MTP -493G/T gene polymorphism is associated with steatosis in hepatitis C-infected patients

The reduction of hepatic microsomal transfer protein (MTP) activity results in fatty liver, worsening hepatic steatosis and fibrosis in chronic hepatitis C (CHC). The G allele of the MTP gene promoter, -493G/T, has been associated with lower transcriptional activity than the T allele. We investigated this association with metabolic and histological variables in patients with CHC. A total of 174 untreated patients with CHC were genotyped for MTP -493G/T by direct sequencing using PCR. All patients were negative for markers of Wilson’s disease, hemochromatosis and autoimmune diseases and had current and past daily alcohol intake lower than 100 g/week. The sample distribution was in Hardy-Weinberg equilibrium. Among subjects with genotype 1, 56.8% of the patients with fibrosis grade 3+4 presented at least one G allele versus 34.3% of the patients with fibrosis grade 1+2 (OR = 1.8; 95%CI = 1.3-2.3). Logistic regression analysis with steatosis as the dependent variable identified genotypes GG+GT as independent protective factors against steatosis (OR = 0.4, 95%CI = 0.2-0.8; P = 0.01). The results suggest that the presence of the G allele of MTP -493G/T associated with lower hepatic MTP expression protects against steatosis in our CHC patients

Mthfr Polymorphic Variant C677t Is Associated To Vascular Complications In Sickle-cell Disease

Vaso-occlusion is a determinant for most signs and symptoms of sickle-cell anemia (SCA). The mechanisms involved in the pathogenesis of vascular complications in SCA remain unclear. It is known that genetic polymorphisms associated with thrombophilia may be potential modifiers of clinical features of SCA. The genetic polymorphisms C677T and A1298C relating to the enzyme methylenetetrahydrofolate reductase (MTHFR), a clotting Factor V Leiden mutation (1691G→A substitution of Factor V Leiden), and the mutant prothrombin 20210A allele were analyzed in this study. The aim was to find possible correlations with vascular complications and thrombophilia markers in a group of SCA patients in Pernambuco, Brazil. The study included 277 SCA patients, divided into two groups: one consisting of 177 nonconsanguineous SCA patients who presented vascular manifestations of stroke, avascular necrosis, leg ulcers, priapism, and acute chest syndrome (group 1); and the other consisting of 100 SCA patients without any reported vascular complication (group 2). Molecular tests were done using either polymerase chain reaction (PCR) restriction fragment length polymorphism or allele-specific PCR techniques. Comparisons between the groups were made using the χ2 test. The 677 CT and TT genotypes showed a significant risk of vascular complications (p=0.015). No significant associations between the groups were found when samples were analyzed for the MTHFR A1298C allele (p=0.913), Factor V G1691 (p=0.555), or prothrombin G20210A mutation (p=1.000). The polymorphism MTHFR C677T seemed to be possibly predictive for the development of some vascular complications in SCA patients among this population. © 2012 Mary Ann Liebert, Inc.16910381043Adekile, A.D., Sickle cell disease in Kuwait (2001) Hemoglobin, 25 (2), pp. 219-225. , DOI 10.1081/HEM-100104030Akinyoola, A.L., Adediran, I.A., Asaleye, C.M., Risk factors for osteonecrosis of the femoral head in patients with sickle cell disease (2008) Int Orthop, 33, pp. 923-926Al-Absi, I.K., Al-Subaie, A.M., Ameen, G., Mahdi, N., Mohammad, A.M., Fawaz, N.A., Almawi, W.Y., Association of the methylenetetrahydrofolate reductase A1298C but not the C677T single nucleotide polymorphism with sickle cell disease in Bahrain (2006) Hemoglobin, 30 (4), pp. 449-453. , DOI 10.1080/03630260600867958, PII R3L8033253622414Al-Saqladi, A.W., Delpisheh, A.H.G., Fijnvandraat, K., Frequency of the MTHFR C677T polymorphism in Yemeni children with sickle cell disease (2010) Hemoglobin, 34, pp. 67-77Andrade, F.L., Annichino-Bizzacchi, J.M., Saad, S.T.O., Costa, F.F., Arruda, V.R., Prothrombin mutant, factor V leiden, and thermolabile variant of methylenetetrahidrofolate reductase among patients with sickle cell disease in Brazil (1998) American Journal of Hematology, 59 (1), pp. 46-50. , DOI 10.1002/(SICI)1096-8652(199809)59:1<46::AID-AJH9>3.0.CO;2-#Arruda, V.R., Von Zuben, P.M., Chiaparini, L.C., Annichino-Bizzacchi, J.M., Costa, F.F., The mutation Ala677 Val in the methylene tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis (1997) Thrombosis and Haemostasis, 77 (5), pp. 818-821Arsov, T., Miladinova, D., Spiroski, M., Factor v Leiden is associated with higher risk of deep venous thrombosis of large blood vessels (2006) Croat Med J, 47, pp. 433-439Ataga, K.I., Orringer, E.P., Hypercoagulability in sickle cell disease: A curious paradox (2003) American Journal of Medicine, 115 (9), pp. 721-728. , DOI 10.1016/j.amjmed.2003.07.011Bayazit, A.K., Kilinc, Y., Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state (2001) Pediatrics International, 43 (6), pp. 592-596. , DOI 10.1046/j.1442-200X.2001.01476.xBezerra, M.A.C., Santos, M.N.N., Araú Jo, A.S., Molecular variations linked to the grouping of a-and b-globin genes in neonatal patients with sickle cell disease in the state of Pernambuco, Brazil (2007) Hemoglobin, 31, pp. 1-6Biselli, J.M., Goloni-Bertollo, E.M., Zampieri, B.L., Haddad, R., Eberlin, M.N., Pavarino-Bertelli, E.C., Genetic polymorphisms involved in folate metabolism and elevated plasma concentrations of homocysteine: Maternal risk factors for Down syndrome in Brazil (2008) Genetics and Molecular Research, 7 (1), pp. 33-42. , http://www.funpecrp.com.br/gmr/year2008/vol7-1/pdf/gmr388.pdfCançado, R.D., Jesus, J.A., Sickle cell disease in Brazil (2007) Rev Bras Hematol Hemoter, 29, pp. 203-206Castro, R., Rivera, I., Ravasco, P., Camilo, M.E., Jakobs, C., Blom, H.J., De Almeida, I.T., 5,10-Methylenetetrahydrofolate reductase (MTHFR) 677CT and 1298AC mutations are associated with DNA hypomethylation (2004) Journal of Medical Genetics, 41 (6), pp. 454-458Engbersen, A.M.T., Franken, D.G., Boers, G.H.J., Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia (1995) Am J Hum Genet, 56, pp. 142-150Ercan, B., Tamer, L., Sucu, N., Pekdemir, H., Camsan, A., Atik, U., Factor VLeiden and prothrombin G20210A gene polymorphisms in patients with coronary artery disease (2008) Yonsei Medical Journal, 49 (2), pp. 237-243. , http://www.eymj.org/2008/pdf/04237.pdf, DOI 10.3349/ymj.2008.49.2.237Fawaz, N.A., Bashawery, L., Al-Sheikh, I., Qatari, A., Al-Othman, S.S., Almawi, W.Y., Factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations among patients with sickle cell disease in Eastern Saudi Arabia (2004) American Journal of Hematology, 76 (3), pp. 307-309. , DOI 10.1002/ajh.20087Frenette, P.S., Atweh, G.F., Sickle cell disease: Old discoveries, new concepts, and future promise (2007) Journal of Clinical Investigation, 117 (4), pp. 850-858. , http://www.jci.org/cgi/reprint/117/4/850, DOI 10.1172/JCI30920Frosst, P., Blom, H.J., Milos, R., A candidate genetic risk factor for vascular disease:A common mutation in methylenetetrahydrofolate reductase (1995) Nat Genet, 10, pp. 111-113Haviv, Y.S., Shpichinetsky, V., Goldschmidt, N., Abou Atta, I., Ben-Yehuda, A., Friedman, G., The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients (2002) Nephron, 92 (1), pp. 120-126. , DOI 10.1159/000064485Kaul, D.K., Finnegan, E., Barabino, G.A., Sickle red cellendothelium interactions (2009) Microcirculation, 16, pp. 97-111Khan, S., Dickerman, J.D., Hereditary thrombophilia (2006) Thrombosis J, 4, p. 15Kordes, U., Janka-Schaub, G., Kulozik, A., Homozygous factor v Leiden mutation in sickle cell anaemia (2002) Br J Haematol, 116, pp. 236-238Kutlar, A., Kutlar, F., Turker, I., Tural, C., The methylene tetrahydrofolate reductase (C677T) mutation as a potential risk factor for avascular necrosis in sickle cell disease (2001) Hemoglobin, 25 (2), pp. 213-217. , DOI 10.1081/HEM-100104029Lahiri, D.K., Nurnberger, J.I., A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies (1991) Nucleic Acids Res, 19, p. 5444Lowenthal, E.A., Mayo, M.S., Cornwell, P.E., Homocysteine elevation in sickle cell disease (2000) J Am Coll Nutr, 19, pp. 608-612Moreira Neto, F., Lourenco, D.M., Noguti, M.A.E., Morelli, V.M., Gil, I.C.P., Beltrao, A.C.S., Figueiredo, M.S., The clinical impact of MTHFR polymorphism on the vascular complications of sickle cell disease (2006) Brazilian Journal of Medical and Biological Research, 39 (10), pp. 1291-1295. , http://www.scielo.br/scielo.php?script=sci_arttext&pid= S0100-879X2006001000004&lng=en&nrm=iso&tlng=en, DOI 10.1590/S0100-879X2006001000004Nagel, R.L., Steinberg, M.H., Genetics of the bS gene:origins, genetic epidemiology, and epistasis in sickle cell anemia (2001) Disorders of Hemoglobin:Genetics, Pathophisiology, and Magement, pp. 711-755. , Steinberg MH, Forget BG, Higgs DR, Nagel RL (eds Cambridge University Press, New YorkOrah, S., Platt, M.D., Hydroxyurea for the treatment of sickle cell anemia (2008) N Engl J Med, 358, pp. 1362-1369Poort, S.R., Rosendaal, F.R., Reitsma, P.H., A common genetic variant in the 38-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase invenous thrombosis (1996) Blood, 88, p. 3698Ramos, C.P.S., Campos, J.F., Melo, F.C.B.C., Frequency of factor v Leiden in individuals under thrombophilia investigation, Recife, Pernambuco, Brazil (2006) Rev Bras Hematol Hemoter, 28, pp. 131-134Reeves, S.G., Meldrum, C., Groombridge, C., MTHFR 677 C> T and 1298 C> T polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer (2009) Eur J Hum Genet, 17, pp. 629-635Ridker, P.M., Miletich, J.P., Buring, J.E., Ariyo, A.A., Price, D.T., Manson, J.A.E., Hill, J.A., Factor V Leiden mutation as a risk factor for recurrent pregnancy loss (1998) Annals of Internal Medicine, 128 (12 PART 1), pp. 1000-1003Robien, K., Ulrich, C.M., 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: A HuGE minireview (2003) American Journal of Epidemiology, 157 (7), pp. 571-582. , DOI 10.1093/aje/kwg024Slavik, L., Krcova, V., Hlusi, A., Molecular pathophysiology of thrombotic states and their impact to laboratory diagnostics (2009) Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 153, pp. 19-26Steinberg, M.H., Predicting clinical severity in sickle cell anaemia (2005) British Journal of Haematology, 129 (4), pp. 465-481. , DOI 10.1111/j.1365-2141.2005.05411.xVan Der Dijs, F.P.L., Schnog, J.-J.B., Brouwer, D.A.J., Velvis, H.J.R., Van Den Berg, G.A., Bakker, A.J., Duits, A.J., Muskiet, F.A.J., Elevated homocysteine levels indicate suboptimal folate status in pediatric sickle cell patients (1998) American Journal of Hematology, 59 (3), pp. 192-198. , DOI 10.1002/(SICI)1096-8652(199811)59:3<192::AID-AJH3>3.0.CO;2-8Volcik, K.A., Blanton, S.H., Tyerman, G.H., Methylenetetrahydrofolate reductase and spina bifida:evaluation of level of defect and maternal genotypic risk in Hispanics (2000) Am J Med Genet, 95, pp. 21-27Zimmerman, S.A., Ware, R.E., Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease (1998) American Journal of Hematology, 59 (4), pp. 267-272. , DOI 10.1002/(SICI)1096-8652(199812)59:4<267::AID-AJH1>3.0.CO;2-WZivelin, A., Rosenberg, M., Faier, S., Kornbrot, N., Peretz, H., Mannhalter, C., Horellou, M.H., Seligsohn, U., A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene (1998) Blood, 92 (4), pp. 1119-112